Hospasol (Sodium Hydrogen Carbonate)

Hospasol is employed as an intravenous solvent and buffering agent in a variety of clinical preparations.

• Adjusting the pH of injectable medications to maintain stability and compatibility.
• Providing bicarbonate ions in IV solutions to help correct metabolic alkalosis when clinically indicated.
• Diluting or reconstituting powdered drugs for intravenous administration, ensuring appropriate concentration.
• Serving as a carrier fluid in parenteral nutrition formulations to deliver nutrients safely.
• Supporting compatibility testing of intravenous admixtures during pharmacy compounding processes.

• Upon intravenous administration, sodium hydrogen carbonate dissociates into sodium ions and bicarbonate anions. The bicarbonate acts as a physiological buffer, reacting with hydrogen ions to form carbonic acid, which rapidly converts to water and carbon dioxide that is eliminated via respiration. This buffering capacity helps maintain extracellular pH within the normal range and supplies bicarbonate ions that can participate in acid‑base balance during infusion of other drugs.

Adverse reactions to Hospasol are generally infrequent, but they may occur as local or systemic responses to the intravenous solvent.

Common

• Mild pain or irritation at the infusion site, often described as a burning sensation.
• Transient increase in serum sodium levels that typically normalizes after the infusion ends.
• Temporary metabolic alkalosis that resolves without intervention once the solvent is discontinued.
• Slight elevation of blood pH without accompanying clinical symptoms, observed in routine laboratory monitoring.

Serious

• Severe hypernatremia leading to neurological symptoms such as confusion, seizures, or coma.
• Acute metabolic alkalosis causing respiratory depression and reduced ventilatory drive.
• Allergic‑type reactions including urticaria, angioedema, or anaphylactoid response requiring medical attention.
• Volume overload in patients with compromised cardiac or renal function, potentially precipitating pulmonary edema.

When using Hospasol, healthcare professionals should observe several precautions to minimize risks and ensure patient safety.

• Assess baseline serum electrolytes, especially sodium and bicarbonate, before infusion.
• Monitor arterial blood gases and pH during and after administration.
• Adjust infusion rate in patients with renal impairment or heart failure.
• Avoid use in individuals with known hypersensitivity to sodium bicarbonate solutions.
• Ensure proper labeling and storage to prevent accidental administration of incorrect concentration.
• Consider fluid balance and avoid excessive volume in patients at risk of overload.

Hospasol may interact with other intravenous agents or systemic medications that affect acid‑base balance or electrolyte status.

Avoid

• Concomitant administration with high‑dose calcium chloride solutions, which can precipitate calcium carbonate.
• Simultaneous infusion of large volumes of hypertonic saline, increasing risk of hypernatremia.

Use with caution

• Co‑administration with other bicarbonate‑containing products, as cumulative alkalinizing effect may lead to metabolic alkalosis.
• Use in patients receiving diuretics that alter sodium balance, requiring closer electrolyte monitoring.
• Infusion alongside medications that are pH‑sensitive, as changes in pH may affect drug stability.
• Administration with blood products, as altered pH may affect coagulation factor activity.